Welcome to our dedicated page for Q32 Bio SEC filings (Ticker: QTTB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Q32 Bio Inc. (QTTB) SEC filings page on Stock Titan provides access to the company’s U.S. Securities and Exchange Commission disclosures, including current reports on Form 8-K that highlight material events. Q32 Bio’s filings reflect its status as a Nasdaq-listed clinical stage biotechnology company focused on alopecia areata and other autoimmune and inflammatory diseases.
Recent Form 8-K filings referenced by Q32 Bio include reports furnished under Item 2.02 for quarterly financial results and corporate updates, and under Item 8.01 for other events such as clinical trial milestones. For example, the company has filed 8-Ks in connection with press releases announcing financial results for specific quarters, as well as an 8-K describing the completion of enrollment in Part B of the SIGNAL-AA Phase 2a clinical trial of bempikibart for alopecia areata. Another 8-K details leadership changes under Item 5.02, including the resignation of a Chief Medical Officer and the appointment of an interim Chief Medical Officer.
Q32 Bio’s 8-K filings also confirm that its common stock, with a par value of $0.0001 per share, is registered pursuant to Section 12(b) of the Exchange Act and trades on Nasdaq under the symbol QTTB. The filings typically attach press releases as exhibits, which are incorporated by reference where specified, and clarify whether the information is being furnished rather than filed for purposes of Section 18 of the Exchange Act.
On Stock Titan, these SEC documents are updated as they become available from EDGAR and are paired with AI-powered summaries that explain the key points in accessible language. Users can quickly see which filings relate to financial results, clinical trial updates, leadership changes, or other corporate events, and can review the underlying forms and exhibits for more detail.
Q32 Bio Inc. ownership disclosure: a group of affiliated entities led by Biotechnology Value Fund, L.P. and related entities reported coordinated holdings representing up to 2,367,524 shares (aggregate) and certain beneficial ownership positions in Q32 Bio common stock. As of the close of business on June 4, 2026, BVF held 1,248,973 shares (5.3%), BVF2 held 929,003 shares (3.9%), and Biotechnology Value Trading Fund OS held 155,156 shares (<1%).
The filing also discloses 150,000 pre-funded warrants exercisable into shares; an Ownership Limit of 9.99% restricts exercises, limiting exercisable pre-funded warrants to 17,524 shares for the reporting group as of June 4, 2026. Several entities in the group disclaim beneficial ownership of other group members' shares; BVF GP, BVF2 GP, BVF GPH, Partners, BVF Inc. and Mark N. Lampert are named as related controlling or deemed owners in the schedule.
Q32 Bio Inc. reporting persons led by RA Capital Management, L.P. disclose beneficial ownership of 2,332,457 shares of common stock, representing 9.8% of the class. The percentage is calculated using May 1, 2026 outstanding shares (16,956,415) plus 6,725,000 shares issued in a private placement that closed on May 28, 2026. The filing states the Fund "delegated to RA Capital the sole power to vote and the sole power to dispose" of the reported shares and that the Reporting Persons "disclaim beneficial ownership" of the securities except as required for Section 13(d) reporting.
Q32 Bio Inc. director and 10% owner Diyong Xu reported indirect purchases totaling 1,875,000 shares of common stock at $8.00 per share. The shares were acquired by affiliated OrbiMed investment funds in a private placement directly from Q32 Bio, with one fund’s indirect holdings reaching 3,502,987 shares after the transactions.
Q32 Bio Inc. reported significant insider buying by OrbiMed-affiliated investment entities. On May 28, 2026, these entities purchased a total of 1,875,000 shares of Q32 Bio common stock at $8.00 per share in a private placement directly from the company.
Following these transactions, one OrbiMed-related account holds 3,502,987 shares of common stock and another holds 625,000 shares, both reported as indirect ownership. The OrbiMed entities, which are 10% owners and have a board representative at Q32 Bio, disclaim beneficial ownership beyond their pecuniary interests.
OrbiMed Advisors LLC and related funds filed Amendment No. 3 to update their stake in Q32 Bio Inc. following a private placement. The reporting persons now may be deemed to beneficially own 4,127,987 common shares, representing 17.4% of the company. Based on 23,681,415 shares outstanding, OrbiMed Private Investments VII, LP holds 3,502,987 shares, or 14.8%, and OrbiMed Genesis Master Fund, L.P. holds 625,000 shares, or 2.6%. These positions reflect a May 2026 PIPE in which OPI VII bought 1,250,000 shares and Genesis bought 625,000 shares at $8.00 per share. The filing also details registration rights agreements providing for resale registration of shares from both the earlier merger financing and the recent private placement.
Q32 Bio Inc. received new investment from several Atlas Venture funds, which filed Amendment No. 1 to their Schedule 13D to update ownership details. Atlas Venture Opportunity Fund III bought 625,000 shares of common stock at $8.00 per share in a 2026 private placement (PIPE), for a total of $5 million.
After this transaction, the Atlas reporting entities collectively beneficially own 2,717,106 shares of Q32 Bio common stock, or about 11.5% of the 23,681,415 shares outstanding as of May 28, 2026. The PIPE added 6,725,000 shares to the prior 16,956,415 shares outstanding. Q32 Bio also agreed to a registration rights agreement, requiring it to file and have declared effective a registration statement covering the resale of PIPE shares and shares issuable from pre-funded warrants within a set timeframe.
Q32 Bio Inc. entered a securities purchase agreement with institutional and accredited investors for a private placement of 6,725,000 common shares and pre-funded warrants to purchase 150,000 shares. The shares are priced at $8.00 each and the warrants at $7.9999 with a nominal $0.0001 exercise price.
The pre-funded warrants are immediately exercisable and subject to a 9.99% beneficial ownership cap, adjustable up to 19.99% with 61 days’ notice. Q32 Bio expects aggregate gross proceeds of approximately $55 million, to be used with existing cash to advance clinical trials for bempikibart and for working capital and general corporate purposes. Closing is expected on May 28, 2026, and the company has agreed to file a resale registration statement for the shares and warrant shares.
Q32 Bio Inc. ownership update: Point72 Asset Management, Point72 Capital Advisors Inc., and Steven A. Cohen report shared voting and dispositive power over 958,768 shares of Common Stock, representing 5.7% of the class as of the close of business on May 14, 2026. The cover page footnote states that as of March 31, 2026 the reporting persons may have been deemed to beneficially own 0 shares. The filing attributes voting and investment power to Point72 Associates under an investment management agreement; Point72 Capital Advisors Inc. is the general partner and Mr. Cohen controls both entities.
Sirenia Capital Management and Alex Silverstein report beneficial ownership of Common Stock in Q32 Bio Inc. The filing states a reported position of 2,057,308 shares, representing 9.9% of the class on a fully‑exercised basis subject to a 9.99% blocker. The percentage calculation uses 14,629,463 shares outstanding as of March 1, 2026. The filing also discloses 1,025,654 shares issuable upon exercise of reported warrants held by the Sirenia Fund and notes the blocker limits exercise to prevent ownership above 9.99%.
Q32 Bio Inc. received an updated Schedule 13D/A from OrbiMed Advisors LLC and OrbiMed Capital GP VII LLC reporting their current stake in the company. Through OrbiMed Private Investments VII, LP, they beneficially own 2,252,987 shares of common stock, representing about 13.3% of Q32 Bio’s 16,956,415 shares outstanding as referenced in a recent quarterly report. The filing notes this percentage fell by more than 1% because the total shares outstanding increased, not because OrbiMed sold shares. OrbiMed states it may buy more or sell shares over time depending on Q32 Bio’s performance and market conditions. An OrbiMed employee, Diyong Xu, sits on Q32 Bio’s board, and any equity awards he receives as a director are assigned back to OrbiMed’s fund. The filing also highlights a registration rights agreement requiring Q32 Bio to file a shelf registration to allow resale of certain shares issued in connection with a prior financing and merger.